Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713895 | 1.00 | KMT2A (0.47) | KMT2AMAPK1CTSKCCR5PPIA | |
| SCHEMBL7177436 | 0.83 | LMNA (0.43) | KMT2ACTSKCCR5PPIAL3MBTL1 | |
| SCHEMBL4718048 | 0.83 | LMNA (0.43) | KMT2ACTSKCCR5PPIAL3MBTL1 | |
| SCHEMBL2082300 | 0.79 | KMT2A (0.51) | KMT2AMAPK1CTSKCTSSDPP8 | |
| SCHEMBL2082301 | 0.79 | KMT2A (0.51) | KMT2AMAPK1CTSKCTSSDPP8 | |
| SCHEMBL4712485 | 0.78 | LMNA (0.45) | CTSKCCR5PPIAUTS2RLMNA | |
| SCHEMBL6167072 | 0.76 | ALDH1A1 (0.44) | KMT2AMAPK1L3MBTL1LMNAHPGD | |
| SCHEMBL8329075 | 0.75 | KMT2A (0.54) | KMT2AMAPK1CTSKCTSS | |
| SCHEMBL8330225 | 0.75 | KMT2A (0.54) | KMT2AMAPK1CTSKCTSS | |
| SCHEMBL8331694 | 0.75 | KMT2A (0.54) | KMT2AMAPK1CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1262477-B1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI SANKYO CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1134219-B1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6825353-B2 | AN AMINE SUBSTITUENT AT THE 7-POSITION OF THE QUINOLONE-CARBOXYLIC ACID DERIVATIVE IS PRODUCED; BACTERICIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6573260-B1 | Antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1262477-A1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1258478-A1 | PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACIDS AND INTERMEDIATES THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1134219-A1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | PGD, PPA1, FASTKD1 | KMT2A 4178/4885MAPK1 365/4885CTSK 1792/4885 |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | NQO2, QPCT, QARS1 | KMT2A 2429/4885MAPK1 2580/4885CTSK 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.